Endocrine and clinical results in administering lisuride for inhibiting lactation.
Lisuride is a potent direct Dopamine agonist and has an effective Prolactin-lowering effect. 64 post-partum women have been divided in two groups: 44 patients with personal reasons to inhibit lactation and 20 patients normally breast-feeding, as control group. The inhibition of lactation has been carried out with Lisuride using 3 X 0.2 mg daily over 10 days, starting within 24-28 hours from delivery. In all the patients we have dosed Prolactin (PRL), LH, FSH, 17-beta Estradiol (E2) in basal conditions (1st day after delivery) and on the 5th and 10th day of assumption of the drug. At the 10th day-control the inhibition of lactation, without symptoms, has been obtained in 39 out of 44 patients treated (86.3%). It is clear how, in comparison with the control group, Lisuride leads to a rapid fall of PRL and seems to promote an earlier restoration of hypothalamus-pituitary-ovary axis, as is shown by the behaviour of gonadotropin and estradiol.
D000328:Adult; D004873:Ergolines / Q000494:pharmacology*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D008090:Lisuride / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D007986:Luteinizing Hormone / Q000097:blood; D011247:Pregnancy; D011388:Prolactin / Q000097:blood; D013997:Time Factors
D004873:Ergolines; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008090:Lisuride